Michael Cola

Part of AstraZeneca PLC, Astra Merck, Inc. is a company that sells pharmaceutical products. The company is based in Orlando, FL. The company was founded by Myrtle S. Potter, Thomas A. McCourt. Astra Merck was acquired by Astra AB from Merck & Co., Inc. on July 12, 1998 for $4,400 million.

Life Sciences Pennsylvania (LSPA) is a trade association that represents various entities in the life sciences industry, including biotechnology, medical device, diagnostic, pharmaceutical, research, and investment companies, as well as service providers. The non-profit company is based in Wayne, PA and has subsidiaries in the United States. The organization unifies innovators in the state to make Pennsylvania a leader in the life sciences industry. Founded in 1989, LSPA aims to create a business and public policy environment that encourages and incentivizes the diverse life sciences economy in Pennsylvania. Christopher P. Molineaux has been the CEO of the company since 2009.

Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

Laureate Biopharmaceutical Services, Inc. provides biopharmaceutical development and protein production services. It offers product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The firm's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply. The company was founded in 1981 and is headquartered in Princeton, NJ.

Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986